LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Konica Minolta, Medovate Partner for Anesthesia Safety
Company News

Konica Minolta, Medovate Partner for Anesthesia Safety

February 4, 2021 2 min read Premium comments

Advertisement

Konica Minolta, Medovate Partner for Anesthesia Safety
UGPro Solution and SAFIRA / Courtesy of Konica Minolta Healthcare Americas Inc. and Medovate Ltd
Secondary#konicaminoltahealthcareamericas#medovate#regionalanesthesia

Konica Minolta Healthcare Americas Inc. and Medovate Ltd are teaming up to promote Medovate’s SAFIRA regional anesthesia injection with Konica Minolta’s range of ultrasound-guided procedures in the United States.

SAFIRA or Safer Injection for Regional Anesthesia is a medical device designed to limit injection pressure and automatically stop injection at high pressure. The design is meant to reduce the risk of nerve injury and advance patient safety.

Studies have shown that regional anesthesia improves post-operative analgesia, cuts down on opioid consumption and anesthesia-related side effects. It also decreases length of stay, early rehabilitation and creates higher patient satisfaction than typically found with general anesthesia.

Both the American Society of Regional Anesthesia and Pain Medicine and the European Society of Regional Anesthesia and Pain Therapy recommend regional anesthesia over general anesthesia for COVID-19 patients where possible to reduce virus transmission.

This new partnership is a part of Konica Minolta’s UGPro Solution which combines education, procedures, and imaging equipment to expand the use of regional anesthesia.

“Regional anesthesia delivers numerous benefits for patients, physicians and hospitals, propelling its growth as an important alternative to general anesthesia,” said Eric Sumner, executive vice president of ultrasound sales at Konica Minolta.

“Medovate brings a unique combination of clinical innovation and expertise through its association with the United Kingdom’s National Health Service and we are proud to partner with them in this endeavor. Both Konica Minolta and Medovate are committed to promoting safer regional anesthesia with solutions that deliver clinical efficiency, simplify use and advance better outcomes for patients.”

Konica Minolta’s SONIMAGE HS2 System has an advanced algorithm, Simple Needle Visualization, which enhances needle visibility and improves accuracy of needle placement in ultrasound-guided regional anesthesia. The sensitivity of needle visualization can also be adjusted for different types of tissues.

Advertisement

Using SAFIRA with the SONIMAGE HS2 system turns the procedure into a one physician job, both companies said. Usually, an assistant is needed “…to inject the anesthetic solution at the required pressure while the anesthesiologist inserted the needle tip using ultrasound guidance.”

“Delivering best practices in regional anesthesia by creating value through innovation is a common vision uniting Medovate and Konica Minolta,” said Chris Rogers, sales and marketing director at Medovate.

“As a leading ultrasound manufacturer, physicians make informed decisions at the point-of-care to enhance patient safety, satisfaction, and their clinical experience. We are honored to partner with them to advance the importance and safety of ultrasound-guided techniques for regional anesthesia.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy